Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Positive Symptoms of Schizophrenia: Hallucinations and Delusions01:30

Positive Symptoms of Schizophrenia: Hallucinations and Delusions

201
Schizophrenia is a complex mental health disorder that can manifest with various positive symptoms, including thought, movement, and behavior disorders. These symptoms significantly disrupt cognitive and motor functions, leading to profound effects on an individual's ability to engage with the world.
Thought Disorders
Disorganized and unusual thought processes mark thought disorders in schizophrenia. One key feature is disorganized speech, where an individual's conversation includes...
201
Schizophrenia01:17

Schizophrenia

193
Schizophrenia, a term introduced by Swiss psychiatrist Eugen Bleuler in 1911, describes a severe psychological disorder marked by profound disruptions in attention, thought processes, language, emotion, and interpersonal relationships. The core feature of schizophrenia is psychosis — a state characterized by a fundamental detachment from reality. This disconnection manifests through distorted logic, impaired perception, and atypical behavior, severely affecting the lives of those...
193
Positive Symptoms Schizophrenia: Hallucinations and Delusions01:26

Positive Symptoms Schizophrenia: Hallucinations and Delusions

118
Schizophrenia is a complex psychiatric disorder characterized by a range of symptoms that significantly impact cognition, behavior, and emotional regulation. Among these, the positive symptoms stand out as they involve the addition or exaggeration of normal mental functions, deviating markedly from typical behavior and perception. Hallucinations and delusions are prominent positive symptoms, each profoundly affecting the individual's experience of reality.
Hallucinations
Hallucinations in...
118
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

871
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
871
Negative and Cognitive Symptoms of Schizophrenia01:30

Negative and Cognitive Symptoms of Schizophrenia

108
Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
108
Biological Causes of Schizophrenia01:29

Biological Causes of Schizophrenia

115
Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
115

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aripiprazole once-monthly for patients diagnosed with bipolar I disorder: Number needed to treat, number needed to harm, and likelihood to be helped or harmed.

Journal of affective disorders·2026
Same author

Efficacy and Safety of Lumateperone and Other Atypical Antipsychotics Approved as Adjunctive Treatment for Major Depressive Disorder in the United States: A Network Meta-Analysis.

Advances in therapy·2026
Same author

Navigating long-acting antipsychotic decision-making in schizophrenia: clinical considerations and best practices.

Expert review of neurotherapeutics·2026
Same author

Progress on Pharmacogenetic Tests for Antidepressant Drug Selection Requires Properly Designed Studies.

Journal of clinical psychopharmacology·2026
Same author

The American Society of Clinical Psychopharmacology task force consensus statement on the deprescribing of stimulant medications in adults with ADHD<sup>✰</sup>.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2026
Same author

Aripiprazole Once-Monthly for Patients Diagnosed With Schizophrenia: Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed.

The Journal of clinical psychiatry·2026

Related Experiment Video

Updated: Aug 20, 2025

Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Na&#239;ve Adolescents at High Risk for Psychosis
05:52

Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis

Published on: November 21, 2013

15.0K

Schizophrenia: One Name, Many Different Manifestations.

Justin Faden1, Leslie Citrome2

  • 1Lewis Katz School of Medicine at Temple University, 100 East Lehigh Avenue, Suite 305B, Philadelphia, PA 19125, USA.

The Medical Clinics of North America
|November 19, 2022
PubMed
Summary

Schizophrenia affects 1% of people globally, causing positive, negative, and cognitive symptoms. Current treatments primarily target positive symptoms, with new therapies under investigation.

Keywords:
AntipsychoticsDopamineFirst episode psychosisNeuropathophysiologyPsychopharmacologyPsychosisSchizophrenia

More Related Videos

Investigating the Effects of Antipsychotics and Schizotypy on the N400 Using Event-Related Potentials and Semantic Categorization
12:00

Investigating the Effects of Antipsychotics and Schizotypy on the N400 Using Event-Related Potentials and Semantic Categorization

Published on: November 19, 2014

13.0K
Derivation, Expansion, Cryopreservation and Characterization of Brain Microvascular Endothelial Cells from Human Induced Pluripotent Stem Cells
08:04

Derivation, Expansion, Cryopreservation and Characterization of Brain Microvascular Endothelial Cells from Human Induced Pluripotent Stem Cells

Published on: November 19, 2020

6.5K

Related Experiment Videos

Last Updated: Aug 20, 2025

Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Na&#239;ve Adolescents at High Risk for Psychosis
05:52

Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis

Published on: November 21, 2013

15.0K
Investigating the Effects of Antipsychotics and Schizotypy on the N400 Using Event-Related Potentials and Semantic Categorization
12:00

Investigating the Effects of Antipsychotics and Schizotypy on the N400 Using Event-Related Potentials and Semantic Categorization

Published on: November 19, 2014

13.0K
Derivation, Expansion, Cryopreservation and Characterization of Brain Microvascular Endothelial Cells from Human Induced Pluripotent Stem Cells
08:04

Derivation, Expansion, Cryopreservation and Characterization of Brain Microvascular Endothelial Cells from Human Induced Pluripotent Stem Cells

Published on: November 19, 2020

6.5K

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Schizophrenia is a severe mental disorder affecting about 1% of the global population.
  • It manifests with positive symptoms (hallucinations, delusions), negative symptoms (apathy, lack of pleasure), and cognitive deficits.
  • The etiology is complex, likely involving multiple environmental factors, neurotransmitters, and neurocircuits.

Purpose of the Study:

  • To review the current understanding of schizophrenia's pathophysiology and treatment landscape.
  • To highlight the limitations of existing therapies, particularly for negative and cognitive symptoms.
  • To discuss emerging therapeutic strategies targeting alternative pathways.

Main Methods:

  • Literature review of existing research on schizophrenia.
  • Analysis of current pharmacologic treatments and their efficacy.
  • Exploration of ongoing research into novel therapeutic targets.

Main Results:

  • Dopamine receptor antagonists are effective for positive symptoms but show limited efficacy for negative and cognitive symptoms.
  • The pathophysiology of schizophrenia is multifactorial, involving various neurotransmitter systems.
  • Nondopaminergic medications and alternative receptor targets are under active investigation.

Conclusions:

  • Current antipsychotic medications offer incomplete symptom control in schizophrenia.
  • Further research is crucial for developing more effective treatments, especially for negative and cognitive domains.
  • Integrated care combining pharmacotherapy with psychosocial support is essential for optimal patient management.